



Investor
Presentation

December 2024

FORWARD LOOKING STATEMENTS

This presentation has been prepared by Movano Inc. dba Movano Health (“we,” “us,” “our,” “Movano” or the “Company”) and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and neither this presentation, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding plans with respect to the commercial launches of the Evie Ring and EvieMED; our expectations regarding potential commercial opportunities; planned cost cutting initiatives; anticipated FDA clearance decisions with respect to our products; expected future operating results; product development efforts and product releases; clinical trial and regulatory initiatives; commercial partner activities; as well as our strategies, positioning and expectations for future events or performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

INVESTMENT HIGHLIGHTS: DRIVING THE INTERSECTION OF MED TECH AND CONSUMER DEVICES

FDA Approval with First Mover Advantage

4Q'24 announcement of 510(k) clearance for EvieMED Ring pulse oximeter.

Multiple B2B Opportunities, Engaged Strategic Pipeline

FDA clearance unlocks B2B partnerships for condition management and clinical trials. Progress includes strategic seed investment by Tier 1 Med Device company.



Smart Rings are the New “It” Form Factor

Global wearable market estimated to reach \$145B in 2027. Smart ring adoption growing rapidly, yet only 1 million smart rings sold in 2024.

DTC Tailwind

Expanded Evie Ring D2C launch campaign in 3Q'24. Additional feature upgrades in progress for 4Q'24 and 2025, including Android app.

Proprietary RF Technology Could Address “Holy Grails”

In Fall 2023, MOVE clinical prototype achieved accuracy commensurate with FDA requirements for blood pressure monitoring. Analyzing data from November 2024 follow-on clinical trial.

STRATEGIC MILESTONES – 18 MONTHS



Drive D2C Adoption
of Evie Ring

Q3/Q4 2024



- Improved ring functionality
- Celebrity brand ambassador
- Influencer campaign
- Media blitz
- Best In class customer service

510(k) Clearance Secured;
Launch EvieMED B2B

Q4 2024



- Establish distribution framework for medical device launch
- Build API support for data sharing

Continue Advanced
Research for New
Analytes

2024-2025



- Continue clinical evaluations and data analytics to enhance system accuracy and performance for new analytes
- “Bolt on” FDA submissions, going forward, given foundational 510(k) clearance for EvieMED

Perfect mmWave RF
Tech for Blood
Pressure Solution

2025



- Continued focus on successful clinical trials and algorithm development
- Build and test wearable form factor, drive towards commercial prototype
- Refine RF system-on-chip for commercial opportunity

NEWS AND UPDATES – DECEMBER 2024



D2C

- Evie Ring back in stock 9.17.24.
- Brand partnership with influencer and digital creator Heidi D'Amelio in full swing.
- Product, operations and customer service enhancements bolster expanded launch.
- Android app available for 2024 holiday season.

B2B

- FDA 510(k) clearance for the EvieMED Ring's pulse oximetry feature announced 12.2.24.
- Continued progress made with B2B commercial opportunities that could leverage EvieMED – including a global pharmaceutical company, clinical research organization (CRO) and large payor.

CLINICAL RESEARCH

- In November 2024, Movano Health executed another cuffless blood pressure clinical study with a smaller, more commercially viable device. The new prototype features 12 additional mmWave antennas, delivering enhanced data collection.

TARGETING LARGE CONSUMER & MEDICAL TECHNOLOGY MARKETS




\$16B
TAM



**CONSUMER
DEVICE**



**MEDICAL
DEVICE**








\$39B
TAM

EVIE PRODUCT & TECHNOLOGY OVERVIEW

CONTEMPORARY SMART RING

PERSONALIZED APP EXPERIENCE



Heart Health



Sleep Metrics



Activity Tracking



Menstrual Cycle



Custom Insights

HOW EVIE STACKS UP



	Steps & Activity	Sleep & Sleep Stages	Pulse Rate	SpO2	Skin Temp.	Menstrual Cycle	Mood Logging	Personal Insights	Form Factor/ Design	Price
evie	●	●	★	★	●	●	●	●	Open Ring Design & Portable Charger	\$269 No sub
WHOOP®	●	●	●	⦿*	●	●	●		Screenless Bands	\$20/month with 1-year commit
OURA	●	●	●	⦿*	●	●	●		Closed Ring	\$349-\$499 & \$6/month sub
fitbit	●	●	●	⦿*	●	●	●		Bands and Watches	\$99-\$299

★ FDA clearance for EvieMED Ring
● Full function
⦿ Limited function

*Fitbit, Whoop, and Oura devices deliver nighttime readings only. Evie offers on demand Spot Check function.

D2C BUSINESS DRIVERS



BRAND AMBASSADOR HEIDI D'AMELIO

12M
Social
Followers



INFLUENCER AND UGC CAMPAIGN



MEDIA BLITZ

Tech and Consumer
Press Tour

Updated Product Reviews

Holiday Gift Guides




CUSTOMER ENGAGEMENT AND OUTREACH


150K Lead List

Newsletter Series

Ongoing Blog Content



WEARABLE MARKET GROWING EXPONENTIALLY



WOMEN'S HEALTH FOCUS: IT'S ABOUT TIME



\$44B

2023 US Market Size: Women's Health¹

\$100M

White House Investment in Women's Health²


1000+

Women interviewed to design Evie

1. <https://www.grandviewresearch.com/industry-analysis/womens-health-market>

2. <https://www.whitehouse.gov/briefing-room/speeches-remarks/2024/02/21/remarks-as-prepared-for-delivery-by-first-lady-jill-biden-to-announce-the-100-million-arpa-h-sprint-for-womens-health/>

EVIE US MARKET TAM & COMPOSITION



27% of Women Surveyed Answered
"Extremely or Very Likely" to Buy¹

**~33M
WOMEN**

WE HAVE INSIGHT TO HEALTH ISSUES...



Insomnia



Depression



Heart Disease



Menopause/ Menstrual Health

...AND HOW WE'LL TARGET THEM



Clinical Trials



Corporate Wellness



Traditional Media






Paid Advertisement

EVIE RING D2C OPPORTUNITY

STRATEGIC LAUNCH PLAN FOCUSES ON ENGAGED AUDIENCE MOST LIKELY TO PURCHASE



GROWTH PLAN LEVERAGES ORGANIC CONVERSION, RETAIL EXPANSION AND NEW FORM FACTORS



1. Based on US Population 2023, women ages 18+ extremely or very likely to buy
2. Company analysis

KEY EVIE RING DIFFERENTIATORS



1

Sleek, Smart, Comfortable Hardware

- Open ring design offers comfortable fit
- Rated most aesthetically pleasing smart ring (*Wall Street Journal*)
- Compact, portable recharging case

2


Novel App Design

- Seamlessly tracks key biometric data including menstrual cycle, mood, energy
- Personalized activity and performance goals
- Industry first Daily Summary dynamically displays daily progress

3

AI-Driven Insights


- Identifies correlations, patterns and trends across different vital signs, menstrual health, mood, energy, sleep and activity in longitudinal data




EVIE APP INSIGHTS EXPERIENCE




Passively collected
body data on sleep



Logged symptom +
cycle data



Educational insight based
on her experience



EVIE MED: STRONG B2B PROPOSITION

FDA 510(k) clearance
announced 12.2.24 for
EvieMED Ring



Attractive margin
profile on B2B sales



First mover
advantage:
FDA-cleared
option for
enterprises




New distribution
channel




First B2B
investment +
several beta
programs
underway




SIGNIFICANT NETWORK OF B2B PARTNERS ESTABLISHED



MOVANO HEALTH'S B2B OPPORTUNITY



CURRENT B2B ENGAGEMENTS ACROSS THE HEALTHCARE CONTINUUM



USE CASE #1 – Pharmaceutical Companies



Pharma / Clinical Trials

PROBLEM

- Poor compliance
- Suboptimal trial results
- In-person monitoring is expensive

SOLUTION

- Movano device usage enables better compliance
- Cost of device and monitoring significantly lower than regular office visits
- Movano device enables quicker enrollment, better data, and improved quality of results

TRACTION

- “Major global pharma” Beta I partner
- “Major global pharma” hosts >30,000 patients in clinical trials per year

GROWTH

- 3 near-term pharma clients in pipeline

USE CASE #2 – Payors



Payors

PROBLEM

- Large populations of chronic disease patients
- Costly disease interventions being deployed in cases that could be prevented
- Suboptimal evaluation of economic value associated with some interventions

SOLUTION

- Easy-to-implement monitoring of critical physical health parameters (sleep, blood oxygen, blood pressure, etc.)
- Potential for early detection of dangerous health risks
- Provides longitudinal health data

TRACTION

- “Top 3 US payor” that covers 47 million lives is Beta II partner
- 20% of subscribers are high risk, just 5% of that group represents 500k units

GROWTH

- 2 near-term payor customers in pipeline

USE CASE #3 – Remote Patient Monitoring (RPM)



Remote Patient Monitoring (RPM)

PROBLEM

- Increasing needs to monitor patients remotely, due to broad lifestyle shifts and preferences
- In-office visits involve high cancellations; higher costs for patients and slower throughput for physicians
- Reduced frequency of physician monitoring promote suboptimal health monitoring

SOLUTION

- Regular monitoring reduce costs of healthcare
- Any device or component of an RPM solution must be FDA approved/cleared
- Improves access to healthcare (for patients of limited means, rural areas, complex needs, etc.)

TRACTION

- “Leading US RPM company” Beta II partner, serves >450 healthcare organizations and is the exclusive platform for one of the largest medical device companies in the world

GROWTH

- 2 near-term RPM customers in pipeline

USE CASE #4 – Medical Device Patient Management



Medical Devices (Patient Management)

PROBLEM

- Inability to continuously monitor patients outside physician's office
- Suboptimal patient outcomes
- In-person monitoring is expensive

SOLUTION

- Ability to make real-time adjustments to patient regiment, improving outcomes
- Continuous data feed provides physicians better intelligence
- Reduces friction and cost to delivery patient care

TRACTION

- "Leading med device company" has engaged in initial draft of LOI
- "Leading med device company" serves >200k new patients/devices per year

GROWTH

- 4 near-term medical device customers in pipeline

REMOTE PATIENT MONITORING REDUCES COSTS



Remote Blood Pressure Monitoring

What experts say:

\$6,000 per patient was saved by implementing a mobile application integrated with an Apple Watch and a Bluetooth BP cuff¹

43% lower
likelihood of hospital
readmission at 30 days ¹

***EvieMED
Reduces
Cost to the
Healthcare
System***



Remote SpO2 Monitoring

What experts say:

Reduced costs by \$11,472 & improved outcomes compared to the current standard of care (0.013 QALYs gained)²

87% fewer hospitalizations & **77% fewer deaths**

among patients with access to remote pulse-ox monitoring³

nature reviews cardiology

NIH National Library of Medicine
National Center for Biotechnology Information

1. <https://www.nature.com/articles/s41569-021-00522-7>;
2. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8536499/>;
3. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8536499/>

MEDICAL DEVICE POSITIONING CREATES SIGNIFICANT BARRIERS TO ENTRY IN ENTERPRISE MARKET



To Compete With Movano Health, Companies Would Have To...

1

Create Medical Device Infrastructure

- Implement a Quality Management System (QMS)
- Hire medical device personnel for Quality, Regulatory, and Clinical (QRC)
- Train every employee on Standard Operating Procedures

2

Pursue FDA Clearance

- Establish clinical trials, generate all required documents
- Set up production to comply with FDA Good Manufacturing Practices

3

Establish Post Market Surveillance Functions

- Ongoing QRC initiatives to track product, complaints, CAPAs

Transitioning an existing wearables operation into a medical device company would be **extremely costly** and take **several years to execute**

MATERIAL PROGRESS WITH PROPRIETARY AND PATENTED RF TECHNOLOGY



Why High Blood Pressure Is Known as the Silent Killer

Peter Attia, M.D., author of 'Outlive: The Science & Art of Longevity,' shares how aggressively managing your blood pressure is a key to a longer and healthier life.



Blood pressure & glucose are "holy grail" opportunities



Proprietary RF technology de-risked



Recent BP clinical results unlock opportunity



Strategic investment validates tech and opportunity



Commercial product in 2+ years




BREAKTHROUGH IN BLOOD PRESSURE MONITORING WITH CLINICAL RESULTS IN LINE WITH AN FDA RECOGNIZED STANDARD



	Mean Absolute Difference
FDA Recognized Standard	7.0 mmHg ¹
Movano	5.9 mmHg²

- Cuffless wrist worn device
- Clinical study in 43 subjects
- BP measurements at rest and under stress



¹ Mean Absolute Difference (MAD) required per IEEE 708a-2019 standard for wearable, cuffless blood pressure measuring devices

² Company's algorithm for blood pressure monitoring utilized data from its prototype system combined with the subject's demographic information and a recent blood pressure reading

Movano Health patent summary

US: 30 Issued, 14 Pending (1 allowed)

Foreign: 2 Issued (China/Europe),
3 Pending (1 China/2 Europe)
PCT: 1 Pending

KEY US PATENTS FALL INTO FOUR CATEGORIES

RF IC Architecture (2) Issued

Covers RF IC design, including multi-band mixing and conductor loss mitigation that is critical at high frequencies.

Key Issued Patents:

- Systems for multi-band radar-based sensing (US 11,298,037)
- Methods for multi-band radar-based sensing (US 10,874,314)

Ring (3) Pending

Covers various aspects of the current Evie Ring and charger design, including the 2-piece open-ended construction, production efficiencies, and control efficiencies.

Pending Patents:

- Finger wearable health monitoring device
- Finger wearable devices and methods for producing finger wearable devices
- Ring charging case



RF-Based Health Monitoring (25) Issued (5) Pending

Covers signal processing techniques for generating high resolution pulse wave signal to determine HR, BP, BG level.

Key Issued Patents:

- Systems for RF-based health monitoring utilizing amplitude and phase data (US 11,445,929)
- Methods and systems for monitoring BP using stepped frequency radar with spectral agility (US 11,360,188)
- System for monitoring a physiological parameter that involves coherently combining data from RF-based sensor system (US 11,883,132)
- System for monitoring a health parameter of a person utilizing a pulse wave signal (US 11,786,133)

Machine Learning Applications (3) Issued (6) Pending

Techniques for generating training data and training ML models for health monitoring, and techniques for utilizing ML models for health monitoring, including blood pressure and blood glucose.

Key Issued Patents:

- Methods for training a model for use in RF-based health monitoring (US 11,464,419)
- Methods for training a model for use in radio waved based blood pressure monitoring (US 11,596,321)

CORPORATE SNAPSHOT (NASDAQ: MOVE)



DOLLARS RAISED

\$130M*

YEAR FOUNDED

2018

IP PORTFOLIO:

US 30 patents issued, 14 pending
OUS 2 patents issued, 4 pending

LTM CASH BURN 9/30/24

\$23M

NUMBER OF FTES

32

CASH AT 9/30/24

\$11.3M

CORPORATE ENTITIES:

Movano Inc. dba
Movano Health
Movano Ireland



* The Company is party to an At the Market Issuance Agreement with JonesTrading Institutional Services LLC. Pursuant to the terms of the Issuance Agreement, the Company may sell from time to time through the Sales Agent shares of the Company's common stock.

NASDAQ: MOVE

+1 (415) 651-3172

6800 Koll Center Pkwy.
Pleasanton, CA 94566

www.movanohealth.com
www.eviering.com

